Difficulty: Medium
Average Score: 74%
Practice
A patient with Alzheimer's disease is taking an acetyl cholinesterase inhibitor specifically approved for that indication, primarily because it is quite lipophilic and so enters the CNS well. Which of the following drugs is the patient most likely receiving?
Correct answer
A
Rationale
The correct answer is A) Donepezil. Donepezil is a centrally acting acetylcholinesterase inhibitor commonly used in the treatment of Alzheimer's disease. It is quite lipophilic, which means it has a high affinity for fat tissues and can easily cross the blood-brain barrier to enter the central nervous system (CNS). This property is crucial for a drug targeting cognitive function in Alzheimer's patients, as it needs to reach the brain to exert its therapeutic effects.
Option B) Edrophonium is a short-acting acetylcholinesterase inhibitor used for diagnostic purposes in conditions like myasthenia gravis. It is not approved for the treatment of Alzheimer's disease and is not known for its lipophilicity to cross the blood-brain barrier effectively.
Option C) Neostigmine and Option D) Pyridostigmine are primarily used in the management of conditions like myasthenia gravis and are not approved for Alzheimer's disease treatment. They are not as lipophilic as Donepezil, which limits their ability to penetrate the CNS efficiently to produce therapeutic effects in Alzheimer's patients.
In an educational context, understanding the pharmacokinetic properties of drugs is essential in selecting the most appropriate treatment for various conditions. The ability of a drug to cross the blood-brain barrier, as seen with Donepezil in Alzheimer's disease, is a critical factor in its efficacy. This knowledge helps healthcare professionals make informed decisions when prescribing medications for neurological disorders.
Option B) Edrophonium is a short-acting acetylcholinesterase inhibitor used for diagnostic purposes in conditions like myasthenia gravis. It is not approved for the treatment of Alzheimer's disease and is not known for its lipophilicity to cross the blood-brain barrier effectively.
Option C) Neostigmine and Option D) Pyridostigmine are primarily used in the management of conditions like myasthenia gravis and are not approved for Alzheimer's disease treatment. They are not as lipophilic as Donepezil, which limits their ability to penetrate the CNS efficiently to produce therapeutic effects in Alzheimer's patients.
In an educational context, understanding the pharmacokinetic properties of drugs is essential in selecting the most appropriate treatment for various conditions. The ability of a drug to cross the blood-brain barrier, as seen with Donepezil in Alzheimer's disease, is a critical factor in its efficacy. This knowledge helps healthcare professionals make informed decisions when prescribing medications for neurological disorders.